1.4 Scientific symposia: Improving access to care for leishmaniasis patients and its various forms (VL, CL, PKDL, HIV-VL), including vulnerable groups: the LeishAccess project

Chairs: Fabiana Alves

Presentations:

**Facilitate the uptake and adoption of new diagnostics and treatment options for VL, HIV-VL, and PKDL through systematic, targeted and measurable interventions
**Simon Bolo, Drugs for Neglected Diseases initiative (DNDi), Kenya

**Evaluation of rK28 and Kala-azar Detect rK39 rapid diagnostic tests for VL in Kenya, towards strengthening recommendations for their use and access in Eastern Africa
**Dawn Maranga, FIND, Kenya

**Phase II/ III, Open-Label, Multicenter, Randomized Clinical Trial to Evaluate the Safety and Efficacy of Thermotherapy for the Treatment of Uncomplicated Cutaneous Leishmaniasis Cases
**Endalamaw Gadisa, Armauer Hansen Research Institute, Ethiopia

**Assessment of burden, risk factors, knowledge and practices associated with VL among pastoralists
**Rose Bosire, Kenya Medical Research Institute (KEMRI), Kenya

**Evaluation of measures to improve access to care through decentralization of VL diagnosis and treatment in Turkana County
**Jane Mbui, Kenya Medical Research Institute (KEMRI), Kenya and Dawn Maranga, FIND, Kenya